Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Creo Medical reveals double-first success for Speedboat endoscopic advanced energy device

Speedboat is the first device developed for use with the Welsh company's CROMA generator, which allows doctors to carry out surgical procedures without the need to puncture the skin
Hospital operation
Until now, the device has only been used in a clinical setting in the United Kingdom for lower gastrointestinal procedures

Creo Medical Group PLC (LON:CRO) jumped higher on Thursday after the medical device company announced the successful first use of its Speedboat endoscopic advanced energy device in seven upper gastrointestinal (GI) tract patients in South Africa.

Speedboat is the first device developed for use with the Welsh company's CROMA generator, which allows doctors to carry out surgical procedures without the need to puncture the skin.

READ: Two huge licensing deals help Oxford BioMedica swing to a first-half profit

CROMA is an electrosurgical platform that combines bipolar radiofrequency for precise, localised cutting and microwave technology for controlled coagulation.

The AIM-listed group said Speedboat harnesses the cut and coagulation of the generator to enable the removal of cancerous and pre-cancerous GI growths.

Until now, the device has only been used in a clinical setting in the United Kingdom for lower gastrointestinal procedures.

Craig Gulliford, Creo's chief executive officer, said: "This is a double first for Creo. The use of our lead product, Speedboat, in upper GI procedures and in a clinical setting outside of the UK is a key step in the commercialisation of our technology.”

In early afternoon trading, Creo Medical shares were up 13% at  189.5p.

View full CREO profile View Profile

Creo Medical Group PLC Timeline

Newswire
December 06 2016

Related Articles

bacteria
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
Woman sneezing
September 27 2018
"We look forward to the exciting developments in our early pipeline planned for 2019, and we expect to continue to grow our European business while progressing towards US and German registration for our lead products," said company chairman, Peter Jensen

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use